Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NovantaFRA:1GSN +0.80%88 3-Year EBITDA Growth Rate is 2.80% as of Jun. 2026, which is 71% below its 10-year median of 9.80. GuruFocus rates FRA:1GSN with a GF Score™ of 88/100 and a GF Value™ of €132.27 (Fairly Valued). The stock has 4 warning signs investors should review. Among 2,025 Hardware companies, Novanta ranks better than 51.9% on this metric.
During the past 12 months, Novanta's average EBITDA Per Share Growth Rate was -8.60% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 2.80% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 12.00% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 11.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Novanta was 63.60% per year. The lowest was -21.70% per year. And the median was 9.80% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Novanta 3-Year EBITDA Growth Rate Related Terms
FRA:1GSN vs ST, VNT, ITRI: 3-Year EBITDA Growth Rate Comparison
For the Scientific & Technical Instruments subindustry, Novanta's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novanta 3-Year EBITDA Growth Rate vs Hardware Industry
For the Hardware industry and Technology sector, Novanta's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Novanta's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 2.80% mean?
Novanta (FRA:1GSN) has a 3-Year EBITDA Growth Rate of 2.80% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Novanta and its competitors. This is 71% below median its historical median of 9.80. According to the industry distribution chart, Novanta ranks #974 out of 2025 companies in the Hardware industry, placing it in the top 48.1%.
Is Novanta's 3-Year EBITDA Growth Rate too high?
Novanta's current 3-Year EBITDA Growth Rate of 2.80% is 71% below median its 10-year median of 9.80. The Hardware industry median 3-Year EBITDA Growth Rate is 2.00. Novanta's value of 2.80% is 40% above this industry median. Based on the distribution chart, Novanta ranks #974 out of 2025 companies in the Hardware industry, which is above the industry midpoint. Overall, Novanta has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Novanta's 3-Year EBITDA Growth Rate compare to ST and VNT?
According to the Hardware industry distribution chart, Novanta ranks #974 out of 2025 companies for 3-Year EBITDA Growth Rate. This puts Novanta in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 2.00. Novanta's value of 2.80% is 40% above this benchmark. While the company's 10-year median is 9.80 vs. the industry median of 2.00, Novanta has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Hardware company?
The median 3-Year EBITDA Growth Rate among Hardware companies is 2.00, based on 2,025 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novanta's current 3-Year EBITDA Growth Rate of 2.80% is 40% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Novanta and its competitors. For the Hardware industry, the median 3-Year EBITDA Growth Rate is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novanta's current 3-Year EBITDA Growth Rate is 2.80%, which is 71% below median its own 10-year median of 9.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novanta stock overvalued right now?
Based on GuruFocus' analysis, Novanta (FRA:1GSN) is currently considered Fairly Valued. The stock's GF Value™ is €132.27, compared to a current price of €126.00 — trading 4.7% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 2.80%, which is 71% below median its 10-year median of 9.80 and 40% above the Hardware industry median of 2.00. Novanta's overall GF Score™ is 88/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Novanta (FRA:1GSN), the current 3-Year EBITDA Growth Rate is 2.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novanta (FRA:1GSN) Overvalued in 2026?
Based on GuruFocus' analysis, Novanta stock appears to be undervalued.
The current stock price of €126.00 is trading 4.7% below its estimated GF Value™ of €132.27.
GuruFocus considers Novanta to be Fairly Valued.
Key valuation signals for FRA:1GSN:
3-Year EBITDA Growth Rate: 2.80% (71% below median its 10-year median of 9.80)
GF Value™: €132.27 vs. price of €126.00 (4.7% below fair value)
Industry Position: 40% above the Hardware median (#974 of 2025)
No single metric tells the full story. See the FRA:1GSN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novanta Inc supplies core technology solutions to medical, life science, and advanced industrial OEMs, leveraging proprietary expertise in precision medicine, precision manufacturing, robotics and automation, and advanced surgery. It has two segments: Automation Enabling Technologies and Medical Solutions. Automation Enabling Technologies, which generates the majority of revenue, provides laser beam steering and scanning solutions, laser sources, and robotic and precision motion technologies. The Medical Solutions segment provides medical-grade technologies, including medical insufflators, endoscopic pumps, and integrated operating room technologies. The company operates in the United States, Germany, and other markets, with revenue generated from the United States.
88GF Score
Get the complete analysis for FRA:1GSN
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1GSN has been successfully added to your 
